Treatment of cetuximab-associated cutaneous side effects using topical aplication oh vitamin K1 cream.

@article{Ocvirk2009TreatmentOC,
  title={Treatment of cetuximab-associated cutaneous side effects using topical aplication oh vitamin K1 cream.},
  author={Janja Ocvirk and Matej Rebersek},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2009},
  volume={27 15_suppl},
  pages={e15087}
}
e15087 Background: The EGFR-targeting monoclonal antibody cetuximab has been licensed by the EMEA in combination with chemotherapy for the treatment of 1st line metastatic colorectal cancer (mCRC) patients (pts) whose tumors have KRAS wild type status. The major side effects of cetuximab are cutaneous reactions (approx. 80% of pts.) predominantly consisting of an acne- like rash 60-100%, but also including pruritus, dry skin (35%), desquamation, hypertrichosis and nail disorders (10-40%). If… CONTINUE READING